Drug Profile
Halofuginone - Processa Pharmaceuticals
Alternative Names: Halofuginone hydrobromide; HT-100; PCS-100; Stenorol™; Tempostatin™Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Collgard Biopharmaceuticals
- Developer Akashi Therapeutics; Collgard Biopharmaceuticals
- Class Antifibrotics; Antineoplastics; Hepatoprotectants; Piperidines; Quinazolinones; Skin disorder therapies; Small molecules; Urologics; Vascular disorder therapies
- Mechanism of Action Angiogenesis inhibitors; Collagen type I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Duchenne muscular dystrophy
- Discontinued Bladder cancer; Cancer; Coronary artery restenosis; Hepatic fibrosis; Kidney disorders; Renal fibrosis; Scleroderma
Most Recent Events
- 28 Sep 2022 Halofuginone is still in phase II trials for Duchenne muscular dystrophy in USA (Akashi Therapeutics pipeline, September 2022)
- 05 Nov 2019 Halofuginone is sub-licensed to Processa Pharmaceuticals worldwide
- 21 Apr 2017 Akashi Therapeutics terminates the HALO-DMD-03 phase II trial for Duchenne muscular dystrophy in USA (NCT02525302)